As a part of an integrated quality concept for impurities during drug development, the multidimensional evaluation of impurity profiles by LC-MS/MS coupling is presented using Quetiapine active pharmaceutical ingredient (API) as an example. Although the LC-UV is commonly employed for the impurities and degradant compounds  determination, the LC-MS/MS technique is proposed in this work as a viable modern alternative for the characterization of these compounds. The case study outlines the use of LC-MS/MS technique in developing methods for the separation and identification which enable the determination of both process and degradation impurities.

     The developed methods of the impurity-profile determination allow monitoring impurity profile changes, resulting from both planned and unplanned changes in the synthesis or the API storage. The developed methods also enable the identity confirmation of the studied API, structure elucidation and identification of the impurities from the synthesis route (isolated, synthetised, and those which were not successfully isolated or synthetised), as well as the impurities resulting from the degradation of the studied pharmaceutical substance which were not obtained as standards. The mass spectra, fragmentation spectra and chromatographic information about the order of elution were all used to identify the impurities. The proposed structures of process impurity were additionally confirmed by analysing the route of synthesis of the studied pharmaceutical substance. On the basis of the proposed structures of API degradation impurities their formation mechanisms were presented.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/22952 must be provided.

1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
2. What modern crystallography can add to pharmaceutical research?
3. Antiproliferative and cytotoxic effect of vitamin D₃ and its derivatives on the selected cells with a higher proliferative potential
4. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
5. Pharmaceutical  technologies  – why do they have to be innovative
6. A novel convergent synthesis of the prostaglandin F_2α analogues
7. Development and validation of GCMS method for the control of ethyl and izopropyl methanesulphonates in pharmaceutical substance in a form of mesilate
8. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
9. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
10. Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model
11. Colon cancer treatment with the use of vitamin D analogs and irinotecan 
12. Experimental and theoretical charge density studies on a model analogue of vitamin D
13. Synthetic Technologies of Pharmaceutical Substances
14. The influence of (24R)-1,24- dihydroxyvitamin D₃ on the anticancer activity of 5-fluorouracil in human colon cancer model
15. Method development and validation of an analytical procedure - control of residual 2-iodopropane in Latanoprost
16. A novel synthesis of 19-nor analogs of vitamin D
17. The influence of novel analogs of vitamin D₃ on the antiproliferative activity of cisplatin or doxorubicin on human promyelocytic leukaemia cell line HL-60 
18. Isolation, structural elucidation and characterization of impurities in latanoprost
19. New rosiglitazone salts
20. New calcipotriol analogs, their toxicity and antitumor activity in vivo in comparison to the affinity with VDR and DBP
21. High-yielded method of synthesis of voriconazole.
22. Polimorphism of Active Pharmaceutical Ingredients
23. GC METHOD FOR QUANTITATIVE DETER- MINATION OF RESIDUAL 2-(2-CHLORO- ETOXY)ETHANOL (CEE) AND N-METHYL- 2-PYRROLIDINONE (NMP) IN PHARMACEU- TICAL ACTIVE SUBSTANCE
24. APPLICATION OF GC/MS FOR IDENTYFICATION OF THE SIDEPRODUCTS IN A PROCESS OF PREPARATION OF PRAMIPEXOLE.
25. ANTITUMOR EFFECT OF CISPLATIN OR FLUOROURACIL IN COMBINED TREATMENT WITH (24R)-1,24-DIHYDROXYVITA- MIN D₃
26. COMBINATION OF: IMATINIB, PRI-2191 AND CYTOSTATICS - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
27. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES
28. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.